Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP5 | P51878 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 4/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4787976 | 0.88 | HTR7 (0.53) | HRH4NPC1RAB9APIK3CBCASP1 | |
| SCHEMBL4888066 | 0.88 | HTR7 (0.53) | HRH4NPC1RAB9APIK3CBCASP1 | |
| SCHEMBL4896185 | 0.81 | HRH4 (0.75) | HRH4NPC1RAB9APIK3CBKDM4E | |
| SCHEMBL4786499 | 0.77 | NPC1 (0.55) | NPC1RAB9ACASP1CASP5ACHE | |
| SCHEMBL14005286 | 0.75 | HRH4 (0.47) | HRH4NPC1RAB9APIK3CBKDM4E | |
| SCHEMBL12321054 | 0.73 | FAAH (0.54) | HRH4RAB9AKDM4EACHEHTT | |
| SCHEMBL14005285 | 0.72 | HRH4 (0.54) | HRH4NPC1RAB9APIK3CBKDM4E | |
| SCHEMBL4894189 | 0.71 | HRH4 (0.53) | HRH4NPC1RAB9APIK3CBKDM4E | |
| SCHEMBL20241743 | 0.71 | KDM4E (0.49) | HRH4KDM4EACHEDRD4 | |
| SCHEMBL5029686 | 0.69 | PIK3CB (0.80) | HRH4NPC1RAB9APIK3CBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | HRH4 1565/4885NPC1 363/4885RAB9A 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.